Dutch and US researchers have re-engineered non-druggable compounds that block the transmission and metabolism of the malaria parasite Plasmodium falciparum.
Swiss Versantis AG has raised money in order to advance its liver detoxifying candidate VS-01 from ongoing Phase Ia trials to initial Phase IIa efficacy proof.
https://european-biotechnology.com/wp-content/uploads/2024/04/Versantis.jpg10822048Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-09-19 08:16:112019-09-19 08:16:11Versantis raises CHF16m in Series B financing
https://european-biotechnology.com/wp-content/uploads/2024/04/ICU-banner-666x300.jpg300666Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-09-13 07:47:382019-09-13 07:47:38Inotrem SA raises €39m to provide POC for nangibotide
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2019-09-12_um_07.02.33.png663990Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-09-12 06:22:182019-09-12 06:22:18Ermium Therapeutics bags €6.3m in Series A round
Leiden-based Pharvaris BV received a cash injection that will be used to push PHA121, the very first orally administered hereditary angioedema (HAE) drug.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2019-09-11_um_08.31.36.png519881Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-09-11 07:44:522019-09-11 07:44:52Pharvaris BV raises $66m to advance oral HAE drug
EMA greenlights new medicines
Latest NewsAt its September meeting, the EMA’s CHMP recommended three innovative medicines for EU market approval.
New malaria lead kills 99.9% of pathogens
Latest NewsDutch and US researchers have re-engineered non-druggable compounds that block the transmission and metabolism of the malaria parasite Plasmodium falciparum.
Versantis raises CHF16m in Series B financing
Latest NewsSwiss Versantis AG has raised money in order to advance its liver detoxifying candidate VS-01 from ongoing Phase Ia trials to initial Phase IIa efficacy proof.
Lundback swallows migraine drug maker Alder
Latest NewsDanish Lundbeck AS is has secured a stake in the migraine market by paying US$1.95bn (€1.76bn) to acquire Alder BioPharmaceuticals Inc.
PFF Group NV acquires stake in Autolus Therapeutics
Latest NewsPrague-based PPF Group has acquired a 19.2% stake in Autolus Therapeutics plc, a developer of T cell cancer therapies.
Elcin Barker Ergun becomes Menarini CEO
AppointmentsThe Board of Directors of Menarini Group has appointed Mrs. Elcin Barker Ergun as CEO.
Researchers identify CTLA-4 response marker
Latest NewsGerman and US researchers have found a biomarker that identifies tumours responding to CTLA-4 checkpoint blockers.
Inotrem SA raises €39m to provide POC for nangibotide
Latest NewsFrench biotech Inotrem SA raised €39m to finance Phase IIb efficacy testing of its TREM1 blocker nangibotide (Motrem) in patients with septic shock.
Ermium Therapeutics bags €6.3m in Series A round
Latest NewsParis-based Ermium Therapeutics has completed a Series A financing to develop breakthrough auto-immune therapeutics.
Pharvaris BV raises $66m to advance oral HAE drug
Latest NewsLeiden-based Pharvaris BV received a cash injection that will be used to push PHA121, the very first orally administered hereditary angioedema (HAE) drug.